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Abstract. The objective of this study was to compare clinical, laboratorial, maternal and perinatal results between HELLP Syndrome and 
severe Preeclampsia. An observational study comparing women with HELLP Syndrome (n=71) to women with severe preeclampsia 
(n=253) was done. The authors analyzed the early course of the pathologies and the outcomes in both groups. HELLP syndrome occurred 
in 28% of all the cases and was more frequent at gestational age before 32 weeks (n=39 – 55%) than severe preeclampsia (n=108 - 42%), 
with more newborns weighting less than 1500g (27 – 38.6% vs 65 – 25.6%; p=0.036). Thrombocytopenia below 100 000/µL (aOR, 2.14; 
95% CI, 1.49 – 3.06) and LDH>1 000 UI/L (aOR: 5.17; 95% CI 2.19 – 12.16) were risk factors for HELLP. Maternal morbidity 
(eclampsia, abruptio placentae, and acute renal failure) was similar in both cohorts; eight stillbirths (6 in severe preeclampsia and 2 in 
HELLP Syndrome) occurred. There were no maternal deaths. In conclusion, in this study the authors confirmed that HELLP Syndrome is 
a severe form of preeclampsia with an earlier presentation in pregnancy, worst laboratorial findings and more prematurity rates. 
Keywords: Preeclampsia, thrombocytopenia, maternal and perinatal morbidity, HELLP syndrome 
Introduction 
Although being a leading cause of great maternal and 
perinatal morbidity and mortality, even in developed 
countries, preeclampsia is present in only 2 to 8% of all 
pregnancies [1]. It has higher prevalence in nulliparous and 
is present as a maternal syndrome, characterized by arterial 
hypertension generally with proteinuria, and a fetal 
syndrome, with fetal growth restriction and amniotic fluid 
reduction. It may have several systemic manifestations, 
variable degrees of severity and either an early onset with 
maternal and fetal morbidity, or a late onset, near term, 
with less severity and reduced fetal compromise. 
Preeclampsia is characterized by hypertension 
(systolic and diastolic blood pressure of ≥ 140 and 90 mm 
Hg, respectively, on two occasions, at least 6 hours apart) 
and proteinuria (protein excretion of ≥ 300 mg in a 24 h 
urine collection, or a dipstick of ≥ 1+), developing after 20 
weeks of gestation in previously normotensive women[1] .  
The analysis of the physio-pathological process shows 
that its origins are related to an immunological process 
associated with a defective and insufficient placentation [1, 
2]. Although the placental origins of the disease are largely 
accepted maternal or fetal predisposing factors are also 
considered when an early onset or a high severity are 
present [3]. 
The syndrome characterized by micro-angiophatic 
hemolysis, liver enzymes elevation and thrombocytopenia 
(HELLP syndrome) was individualized in 1982 by 
Weinstein and is considered a severe form of preeclampsia, 
occurring in 0.5% to 0.9% of all pregnancies and 
complicating 10% to 20% of severe preeclampsia cases [4-
6]. It may have a sudden aggravation and even though 
some clinical aspects may be similar to preeclampsia, in 
HELLP syndrome the blood pressure can be normal, the 
proteinuria is not always present and there is more 
expression of inflammation markers [6-8]. 
Additional characteristics of HELLP syndrome 
include higher platelet and coagulation activation, with 
thrombocytopenia, coagulation disorders and disseminated 
intravascular coagulation (DIC) [8]. The Tennessee 
classification defines as characteristics of the disease the 
presence of hemolysis, with total serum lactic 
dehydrogenase greater than or equal to 600 IU/L, serum 
aminotransferases greater than or equal to 70 IU/L and 
platelets less than or equal to 100 000/µL [6]. The 
Mississippi classification proposes the existence of 
categories according to platelet count: class 1 stands for 
less than 50 000/ µL, class 2 for less than 100 000/ µL and 
class 3 for a platelet count less than 150 000/µL [9]. 
Hemolysis is the main finding of this syndrome and 
can be documented by an elevation of serum lactic 
dehydrogenase (LDH), anemia with presence of 
schistocytes in peripheral smear and low haptoglobin 
concentration. The elevation of both aspartate  aminotrans- 
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ferase (AST) and alanine aminotransferase (ALT) are 
mainly due to a hepatic lesion. Low platelet count is a 
result of a higher consumption: activated platelets adhere 
to endothelial cells with a reduced life-span [9, 10]. 
Perinatal morbidity and mortality are greater in 
HELLP syndrome and are related to gestational age of the 
onset of the clinical situation [7]. Excluding cases with no 
doubts in the classification of HELLP syndrome, when 
there is an hepatic involvement and coagulation disorders, 
sometimes the distinction with severe preeclampsia is 
difficult [8, 9]. 
 The aim of this study was to identify factors that can 
distinguish preeclampsia from HELLP syndrome. We 
analyzed the early or late onset of the disease, based in 
clinical features and laboratorial findings, and the results in 
terms of maternal and fetal morbidity.  
 
Materials and Methods 
We reviewed the medical records of women diagnosed 
with severe preeclampsia or HELLP syndrome between 
January 1, 2008 and December 31, 2013 in a tertiary 
perinatal care center in Lisbon, Portugal.  
Socio-demographic, clinical and laboratorial data were 
analyzed. Classification criteria for preeclampsia diagnosis 
were defined according to guidelines of the International 
Society for the Study of Hypertension in Pregnancy 
(ISSHP) [11] and from the American College of Obstetrics 
and Gynecology (ACOG) [12]. 
According to ACOG criteria (2013) we classified as 
severe preeclampsia cases with a systolic arterial pressure 
(SAP) greater than or equal to 160 mm Hg and a diastolic 
arterial pressure (DAP) greater than or equal to 110mm Hg 
on two occasions 4 hours apart and the occurrence of any 
of these findings: impaired liver function as indicated by 
abnormally elevated blood concentrations of liver 
enzymes, significant proteinuria (≥300 mg/dL) per 24 hour 
urine collection, severe and persistent right upper quadrant 
or epigastric pain,  headaches or visual disturbances, serum 
creatinine concentration values greater than 1.1mg/dL or 
pulmonary edema. Fetal compromise due to maternal 
placental insufficiency may be presented as fetal growth 
restriction, oligo-hydramnios, disturbed Doppler 
velocimetry with absent or reversed end diastolic flow in 
umbilical artery or other fetal vessels. If established before 
34 weeks, preeclampsia was classified as of early onset 
and as of late onset if the diagnose was done only after 34 
weeks. According to the ACOG we defined fetal growth 
restriction as an estimated fetal growth at ultrasound < 10th 
percentile or an abdominal circumference < the 10th 
percentile for a given gestational age [12]. We defined low 
birth weight as a newborn weight lesser than 2,500g and 
extremely low birth weight as a newborn weight lesser 
than 1,500g. 
The management during pregnancy consisted in 
symptomatic treatment, maternal condition stabilization, 
and eventually pregnancy termination when the risks of 
pregnancy continuation outweighed the benefits for either 
the mother or the fetus. 
The Mississippi criteria were applied for HELLP 
syndrome classification  [10,13,14],   with  the   categories’  
 
TABLE 1 
PREECLAMPSIA AND HELLP: SOCIO-DEMOGRAPHIC  
DATA AND  CLINICAL EVALUATION 
 
PE: preeclampsia; BMI: body mass index; CH: chronic hy-
pertension; AH: Arterial hypertension; GA: gestational age; 
UAD: Umbicial artery Doppler; FGR: fetal growth restric-
tion; MgSO4: Magnesium sulfate; * Fisher exact test.  
 
division according to the number of platelet count, 
impaired liver function (AST or ALT) and lactate 
dehydrogenase (LDH) always under  600 IU/L. We also 
considered this syndrome as early or late onset, if the 
disease criteria were established before or after 34 weeks. 
For a complete evaluation, clinical and laboratorial 
parameters were associated with fetal status study, by 
ultra-sonographic assessment of fetal growth and Doppler 
velocimetry of uterine, umbilical and middle cerebral 
arteries and ductus venoso, for evaluation of fetal 
adaptation to an insufficient placental perfusion. 
We used anti-hypertensive therapy to stabilize 
maternal hypertension and to prevent cerebrovascular 
events, when arterial pressure was equal or greater than 
160/100 mm Hg or with lower values associated with other 
symptoms, such as headaches or epigastric pain. 
Magnesium Sulfate was used for convulsions prophylaxis. 
When gestational age was lesser than 34 weeks 6 days, 
antenatal corticosteroid therapy was used for fetal lung 
maturation. 
When maternal platelet count was lesser than 80,000/ 
µL we started corticosteroid therapy,  according  to  Missi- 
PE HELLP Adjusted OR 
 (n = 253) (n = 71) (95% CI)
Age   
   Median 30.5/6.6 31.3/6.7 1,009 (0.969 – 1.051) 0.65
   Min-Max. 14 – 45 17 – 45
   ≥35 years 81(30.9%) 24(33.3%) 0.895 (0.513 – 1.560) 0.696
Ethnicity 
  Caucasian 156 (63.0%) 44 (64.7%)
 Afro-American 66 (26.7%) 17 (25.0%) 0.813 (0.548 – 1,206) 0.303
  Asiatic 3 (1.2%)
Parity
   Nulliparous 164 (68.6%) 41 (68.3%) 1,088 (0.792-1.496) 0.602
   Multiparous 75 (31.4%) 19 (31.7)
BMI
   Median/SD 25.7/5.6 25.0/4.5 0.968 (0.888 -1.056) 0.464
   ≥25 59 (53.6%) 11 (44%) 0.384
   ≥30 25 (22.7%) 5 (20%) 0.767
CH/HT in previous
pregnancy
67 (26%) 8 (11.1%) 1.122 (1.008-1.249) 0.034*
Diabetes 27 (10.7%) 6 (8.4%) 0.993 (0.885 – 1.115) 0.907
HT Therapy
   Labetalol 64(24.5%) 17 (23.6%)
   Nifedipine 41(15.7%) 9 (12.5%)
   Association 78 (29.9%) 17 (23.6%)
   No therapy 39(14.9) 22(30.6%) 0.804 (0.672 – 0.962) 0.017
GA at incoming   
   Median/SD 33.3/4.1 33.07/ 4.4
   IG <32s 81 (32%) 32 (45.1%) 1.988 (1.168-3.384) 0.011
   IG <34s 108 (42.2%) 39 (54.9%) 1.670 (0.984-2.835) 0.057
UAD altered <34s 54 (56%) 17 (51,5%) 0.969 (0.606-1.549) 0.896
FGR 101 (41.1%) 22 (31.4%) 0.741 (0.427 – 1.287) 0.288
Therapy
   MgSO4 153 (58.6%) 50 (70.4%) 0.976 (0.628 – 1.518) 0.915
   Fetal corticotherapy 102 (94.4%) 36 (92,3%) 1.417 (0.337 – 5.962) 0.635
   Maternal 
   corticotherapy 
13 (5.2%) 35 (50%) 16.688 (8.196-33.982) >0.001
Variable p
172 
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TABLE 2  
LABORATORIAL DATA 
 
AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
LDH: lactate dehydrogenase. 
 
ssippi protocol [10]. 
The data was registered in an informatics database. To 
compare categorical variables between the study groups, 
Qui-square test or extension to exact Fisher test were used; 
to analyze continuous variables the non-parametrical test 
of Mann-Whitney was used. Univariate analysis was used 
to assess differences in baseline demographic and 
pregnancy characteristics and in the outcome among the 2 
groups. Unadjusted odds ratios (ORs) with 95% 
confidence intervals (CIs) were calculated to quantify the 
risk of severe preeclampsia and HELLP syndrome. 
Multivariate logistic regression was used to calculate 
adjusted odds ratios (aORs) and 95% confidence intervals 
(95% CI) for the outcome of HELLP syndrome. All 
statistical analysis was performed with Statistical Package 
for Social Sciences (SPSS) version 20.0 (SPSS Inc., 
Chicago, IL). Tests with probability values of α < 0.05 
were considered significant. 
 
Results 
In the period in a total of 33 620 deliveries, 324 cases 
In the period of the study, in a total of 33620 
deliveries, 324 cases of severe preeclampsia occurred, 
representing a prevalence of 0.9%. According to clinical 
and laboratory parameters the diagnosis of severe 
preeclampsia was present in 253 cases while HELLP 
syndrome in 71, resulting in a HELLP syndrome 
prevalence of 28% among all cases of severe preeclampsia 
and of 0.2% among all deliveries.  
The median maternal age was similar in both groups 
(30.5 years in severe preeclampsia and 31.3 years in 
HELLP syndrome) (p = 0.65); 30.9% of the women were 
older than 35 years in severe preeclampsia and 33.3% in 
HELLP syndrome (p = 0.69). Most of the women were 
nulliparous (68.6% in preeclampsia and 68.3% in HELLP 
syndrome), without differences between the two groups (p 
= 0.60). A history of hypertension was more frequent in 
preeclampsia group (aOR, 1.12; CI, 1.01-1.25); there were 
no differences in ethnicity and body mass index (BMI) 
(Table 1). Gestational age at the diagnosis was the same in 
both groups (33 weeks); no differences were found in 
doppler flow velocimetry (p = 0.34) or fetal growth 
restriction (FGR) (p = 0.29) (Table 1). 
The clinical classification and differences in severe 
preeclampsia and HELLP syndrome were based on 
laboratory tests results: elevated aspartate aminotransferase 
(AST) (p < 0.001), elevation in alanine aminotransferase 
(ALT) (p <0.001), lactate dehydrogenase (LDH) >1 
000UI/L (p <0.001) and platelet count <100 000/µL (p 
<.001). HELLP syndrome class 1 or 2 was present, 
according to Mississippi criteria when platelet count <100 
000/ µL (41% of HELLP cases) or <50 000/ µL (24% of 
HELLP cases) (Table 2). There were no differences in 
other laboratorial results, such as hemoglobin (p=0.4), 
hematocrit (p = 0.57), uric acid (p = 0.37) or proteinuria (p 
= 0.84), but haptoglobin <20 g/L was significantly more 
frequent in HELLP syndrome (p = 0.04) (Table 2). 
The early onset of the disease (<34 weeks) was more 
frequent in HELLP syndrome cases (55% vs 42%). 
Compared with the late onset cases, arterial pressure was 
higher when the disease established before 34 weeks, with 
higher need for anti-hypertensive drugs in association (p = 
0.002). Fetal growth restriction was more frequent (p< 
0.001) as well as elevated pulsatility index (IP) doppler 
velocimetry (p < .001) (Table 3). 
The newborn median weight was similar in 
preeclampsia and HELLP cases (2027g vs 1861g) (p = 
0.104), although the HELLP syndrome group had more 
newborns under 1500g (a OR 1.82; CI, 1.10 – 3.18) (p = 
0.036) (Table 4). 
Antenatal glucocorticoid for fetal lung maturation was 
used in 94% of preeclampsia and in 92% of HELLP 
syndrome cases (Table 1). Corticosteroids were 
administered for maternal severe or moderate 
thrombocytopenia in 50% of HELLP cases and only in 
5.2% of preeclampsia cases (p > 0.001) (Table 1). No 
differences were found in severe preeclampsia cases and in 
class 3 of HELLP cases, in pregnancy results or in 
newborn morbidity (Table 3). There were 6 stillbirths 
(2.5%) in preeclampsia and 2 (3.3%) in HELLP syndrome. 
Three occurred between 31 and 35 weeks after placental  
  
Preeclampsia HELLP syndrome         Adjusted OR 
(n = 253) (n = 71)            (95% CI)
Hematocrit
   Med/DP 3.,7/4.8 36/4.3 0.572
   Mín-Max 22-49 28-46
Hemoglobin
   ≥13g 68 (27.0%) 18 (25.4%) 0.4
   ≥10-<13g 157 (62.3%) 42 (59.2%)
   <10g 25 (9.9%) 11 (15.5%)
Uric Acid
   Med/DP 6.3/1.6 5.9/1.4 0.368
   Mín-Máx 3.1-11.8 2.0-9.2
AST
   Normal 151 (60.6%) 12 (16.9%) 3.341 (2.371-4.707) <0.001
   Altered 51 (20.5%) 15 (21.1%)
   Duplicated 44 (17.7%) 43 (60.6%)
ALT
   Normal 161 (64.7%) 16 (22.5%) 3.112 (2.253-4.300) <0.001
   Altered 39 (15.7%) 9 (12.7%)
   Duplicated 45 (18.1%) 45 (63.4%)
LDH
   Normal 120 (47.6%) 11 (15.5%) 3.811 (2.592-5.604) <0.001
   Altered 93 (36.9%) 15 (21.1%)
   >1000 IU/L 29 (11.5%) 43 (60.6%)
Platelets
   ≥100 000 µL 212 (83.8%) 20 (28.2%) 2.885 (2.077-4.009) <0.001
   <100 000 µL 22 (8.7%) 29 (40.8%)
   <50 000 µL 2 (0.8) 17 (23.9%)
Haptoglobin
   <20 g 15 (6.0%) 27 (38.0%) 1.246 (1.011- 1.536) 0.039
Proteinuria
   <100 89 (35.4%) 29 (41.4%) 0.844
   ≥100-<500 64 (25.4%) 15 (21.4%)
   ≥500 61 (24.2%) 17 (37.2%)
Variable p
173 
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TABLE 3 
DIAGNOSIS BEFORE AND AFTER 34 WEEKS 
 
 
PE: Preeclampsia; AUD: Arterial uterine Doppler; FGR: Fetal growth restriction. 
 
 
abruption; five occurred between 24 and 26 weeks with an 
early and severe fetal growth restriction (table 4). There 
were no maternal deaths but there were two cases of 
eclampsia, six of coagulopathy after placental abruption, 
two cases of renal acute failure. Post-partum HELLP 
syndrome was diagnosed in 21% of the cases (table 4). 
After using multivariate logistic regression we identified 
thrombocytopenia <100 000/µL (aOR: 2.14; p <.01) and 
ALT >1000 UI/L(aOR:5.17; p <.001) as factors 
influencing HELLP syndrome diagnosis(table 5). 
 
Discussion 
In this comparative study, we tried to identify specific 
characteristics of HELLP syndrome. In the studied period, 
in a total of 33 620 deliveries, 324 cases of severe 
hypertensive disease were verified, with a prevalence of 
0.9%. The prevalence of HELLP syndrome was 0.2% and 
complicated 27% of the cases of severe preeclampsia, 
results similar to other studies [10, 12, 13]. We didn’t find 
any differences in socio-demographic aspects nor in parity, 
in contrast to other studies, where multiparous and 
advanced maternal age are is more frequent in HELLP 
syndrome [6]. These results may be related to a greater 
prevalence of nulliparity in women with advanced age and 
with a reduced representation of multiparous women in our 
studied women, which may be an expression of delaying 
childbearing age. History of hypertensive disease was 
more frequent in severe preeclampsia cases than in HELLP 
syndrome. Arterial pressure values were greater, with 
higher need of anti-hypertensive drugs in severe 
preeclampsia cases, which is also present in other studies 
[6, 8, 14, 15].  
Early onset of the disease, and extremely low birth 
weight, were more frequent in HELLP syndrome, 
supporting a more severe clinical picture in these cases, 
which is similar to other reports [8, 15]. An expectant 
attitude before 34 weeks was more frequent in severe 
preeclampsia than in HELLP syndrome cases, because in 
the latter there was a more frequent deterioration of clinical 
situation, determining   an  urgent   pregnancy  termination.  
 
TABLE 4. 
PREGNANCY OUTCOME* 
 
*Univariate analysis; PE: preeclampsia; PA: Placental abruption; 
ARF: Acute renal failure; GA: gestational age; NB: newborn. 
 
 
TABLE 5. 
HELLP SYNDROME: MULTIVARIATE ANALYSIS 
 
LDH: Lactate dehydrogenase. 
 
 
Nevertheless, in 92% of HELLP syndrome cases, it was 
possible to administrate antenatal corticosteroid for fetal 
lung maturation. 
In the presence of moderate or severe thrombo-
cytopenia Dexametasone was used, according to 
Mississippi protocol, for a faster mother recovery [14]. 
There was an elevation of platelet count, allowing not  only  
HELLP 39 (54.9%) PE 108 (42.2%) HELLP 32 (45.1%) PE 148 (57.8%)
Antihypertensive 
therapy association
1.78 (1.21-2.31) 0.002
AUD  altered 4.21 (2.92-6.06) <0.001
FGR 2.72 (1.71-4.32) <0.001
Cesarean section 3.93 (2.24-6.95) <0.001
FGR 0.698
Cesarean section 0.772
AUD altered 0.876
Delivery <34s 0.19
Newborn weight <1500g 0.313
p
71 (49.3%)
73 (52.5%) 52 (28.9%)
112 (62.2%)
Adjusted OR
(95% CI)
37 (20.7%)
18 (10.3%)
58 (26.5%)
<34w
(n = 147)
≥34w
(n = 180)
52 (35.4%)
26(17.2%)
93 (42.3%) 14 (56%)
88 (40%)
162 (73.3%)
9 (36%)
Variable
Severe PE
(n = 226)
HELLP
(n = 25)
9 (36%)
3 (15.8%)
19 (76%)
123 (86.6%)
Obstetric outcome 
Platelets≥100 000
PE HELLP Adjusted OR
(n = 253) (n = 71) (95% CI)
PA 4 (1.7%) 2 (2.8%)
Eclampsia 2 (0.8%) 1 (1.4%)
Fetal death 6 (2.4%) 2 (2.8%)
ARF 2 (0.8%) 2 (2.8%)
HELLP after birth 15 (21.1%)
GA at delivery (median) 35weeks 33weeks 0.329
   <34weeks 108(42.2%) 39 (54.9%) 0.50 (0.29 – 0.85) 0.057
   <32weeks 81 (32%) 32 (45.1%) 0.011
Attitude
   Delivery 160 (61.1%) 42(58.3%) 0.675
   Expectant <34 weeks 61 (56.5%) 19 (48.7%) 0.404
Labour induction 120 (46.5%) 27 (37.5%) 0.601
Vaginal birth 70(27.2%) 18 (25.0%) 0.92
Cesarean 187 (72.5%) 54 (75.0%)
NB weight Median/DP 2027g /837 1861g/836 1.82 (1.04-3.18)
   <1500g 65(25.6%) 27 (38.6%)
   <2500g 182 (71.7%) 50 (71.4%)
pVariable
Variable Adjusted OR (CI 95%) p
Platelets <100 000/ µL 2.14 (1.49 – 3.06) <.001
LDH >1000IU/L 5.17 (2.19 – 12.16) <.001
174 
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epidural anesthesia, but also a reduction of transfusion 
needs. The length of hospital staying was similar to severe 
preeclampsia cases and we maintain this protocol, even if 
there is not an evidence supporting this attitude. 
The Mississippi classification proposes the existence 
of classes according to platelet count. The class 3 with a 
platelets count less than 150 000/ µL is very similar to 
severe preeclampsia cases, when compared to clinical and 
laboratorial results. 
The early and sudden onset, the elevation of liver 
enzymes and thrombocytopenia are characteristic of 
HELLP syndrome severity. 
In this study, thrombocytopenia < 100 000/µL, and 
elevation of the liver function tests, were the identification 
factors of this syndrome. When multivariate analysis was 
done, thrombocytopenia < 100 000/µL and lactate 
dehydrogenase more than 1000UI/L, are the significant 
risk factors for this syndrome. 
Although this is a retrospective study with known 
limitations, we think that it has a significant number of 
cases, with classification and management protocols based 
on international guidelines, making possible the 
comparative evaluation between severe preeclampsia and 
HELLP syndrome concerning early onset cases, severity, 
and the decision of optimizing the correct moment of 
pregnancy termination. 
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